The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.
Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.
June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.
Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.
The drug manufacturer alleges the federal government filed for the Truvada prevention patent without their knowledge.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case
The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.
Many fear the push to put more people on the new brand-name drug before Truvada goes generic this year.
Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.